Pfizer And INmune Bio: Seeking The Blockade Of Tumor Necrosis Factor Alpha For Alzheimer`s Disease
(WorldNews Health)

Pfizer`s (PFE) decision not to pursue clinical trials for Enbrel (etanercept) for the prevention and treatment of Alzheimer`s disease may have been based in part on an analysis of the likelihood for success. However, it is more difficult to excuse the company`s decision not to release data suggesting that the drug appeared to significantly reduce the risk for Alzheimer`s disease. Some studies on Enbrel and Alzheimer`s disease did exist in the public record, but if Pfizer had come forward with its information, it would have put a much greater spotlight on the potential of Enbrel to prevent and treat Alzheimer`s disease. Enbrel is a tumor necrosis factor alpha blocker that...